Acute toxicity of the bowel after stereotactic robotic radiotherapy for abdominopelvic oligometastases

References

• Mendez Romero A, Wunderink W, van Os RM, et al. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. Int J Radiat Oncol Biol Phys. 2008;70:1447–1452.
   PubMed Web of Science ®Google Scholar
• Mokhles S, Nuyttens JJ, Maat AP, et al. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis. Ann Surg Oncol. 2015;22:316–323.
   PubMed Web of Science ®Google Scholar
• Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–1076.
   PubMed Web of Science ®Google Scholar
• Prevost JB, Voet P, Hoogeman M, et al. Four-dimensional stereotactic radiotherapy for early stage non-small cell lung cancer: a comparative planning study. Technol Cancer Res Treat. 2008;7:27–34.
   PubMed Web of Science ®Google Scholar
• Baglan KL, Frazier RC, Yan D, et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2002;52:176–183.
   PubMed Web of Science ®Google Scholar
• Robertson JM, Lockman D, Yan D, et al. The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:413–418.
   PubMed Web of Science ®Google Scholar
• Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76:48–53.
   PubMed Web of Science ®Google Scholar
• Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823–830.
   PubMed Web of Science ®Google Scholar
• Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008;112:650–658.
   PubMed Web of Science ®Google Scholar
• Ponti E, Ingrosso G, Carosi A, et al. Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: a single-center experience. Clin Genitourin Cancer. 2015;13:e279–e284.
   PubMed Web of Science ®Google Scholar
• Rwigema JC, King C, Wang PC, et al. Stereotactic body radiation therapy for abdominal and pelvic oligometastases: dosimetric targets for safe and effective local control. Pract Radiat Oncol. 2015;5:e183–e191.
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Bignardi M, Alongi F, et al. Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: feasibility and clinical preliminary results. Acta Oncol (Stockholm, Sweden). 2011;50:528–538.
   PubMed Web of Science ®Google Scholar
• Murphy JD, Christman-Skieller C, Kim J, et al. A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010;78:1420–1426.
   PubMed Web of Science ®Google Scholar
• Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008;72:678–686.
   PubMed Web of Science ®Google Scholar
• Bae SH, Kim MS, Cho CK, et al. Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies. Int J Radiat Oncol Biol Phys. 2012;84:e469–e474.
   PubMed Web of Science ®Google Scholar
• Banerjee R, Chakraborty S, Nygren I, et al. Small bowel dose parameters predicting grade >/= 3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent validation study comparing peritoneal space versus small bowel loop contouring techniques. Int J Radiat Oncol Biol Phys. 2013;85:1225–1231.
   PubMed Web of Science ®Google Scholar
• Gunnlaugsson A, Kjellen E, Nilsson P, et al. Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncol (Stockholm, Sweden). 2007;46:937–944.
   PubMed Web of Science ®Google Scholar
• Roeske JC, Bonta D, Mell LK, et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol. 2003;69:201–207.
   PubMed Web of Science ®Google Scholar
• Agresti A, Finlay B. Statistical methods for the social sciences. 4th ed. Upper Saddle River (NJ): Pearson Prentice Hall; 2009.
   Google Scholar
• Robertson JM, Sohn M, Yan D. Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability model. Int J Radiat Oncol Biol Phys. 2010;77:66–72.
   PubMed Web of Science ®Google Scholar
• Nishino M, Jagannathan JP, Ramaiya NH, et al. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010;195:281–289.
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Ronchi S, Orecchia R. Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?. Rep Pract Oncol Radiother. 2015;20:472–483.
   PubMedGoogle Scholar
• LaCouture TA, Xue J, Subedi G, et al. Small bowel dose tolerance for stereotactic body radiation therapy. Semin Radiat Oncol. 2016;26:157–164.
   PubMed Web of Science ®Google Scholar
• Tho LM, Glegg M, Paterson J, et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys. 2006;66:505–513.
   PubMed Web of Science ®Google Scholar
• Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am J Clin Oncol. 2010;33:157–163.
   PubMed Web of Science ®Google Scholar
• Kang JK, Kim MS, Kim JH, et al. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis. 2010;27:273–278.
   PubMed Web of Science ®Google Scholar
• Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl. 1985;8:S13–S19.
   PubMedGoogle Scholar